BioLight Life Sciences (BioLight Life Sciences) Net Cash per Share : $0.02 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). BioLight Life Sciences's Net Cash per Share for the quarter that ended in Dec. 2023 was $0.02.

The historical rank and industry rank for BioLight Life Sciences's Net Cash per Share or its related term are showing as below:

BOLT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.15 Med: 1.75 Max: 34.43
Current: 0.88

During the past 12 years, the highest Price-to-Net-Cash Ratio of BioLight Life Sciences was 34.43. The lowest was 0.15. And the median was 1.75.

BOLT's Price-to-Net-Cash is ranked better than
56.52% of 867 companies
in the Biotechnology industry
Industry Median: 3.92 vs BOLT: 0.88

BioLight Life Sciences Net Cash per Share Historical Data

The historical data trend for BioLight Life Sciences's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences Net Cash per Share Chart

BioLight Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

Get a 7-Day Free Trial

0.16

0.24

0.16

0.07

0.03

BioLight Life Sciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Cash per Share	Get a 7-Day Free Trial															0.13	0.10	0.06	-0.32	0.02

Competitive Comparison of BioLight Life Sciences's Net Cash per Share

For the Biotechnology subindustry, BioLight Life Sciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLight Life Sciences's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where BioLight Life Sciences's Price-to-Net-Cash falls into.

BioLight Life Sciences Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

BioLight Life Sciences's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.258	-	0.823	-	0.137)	/	48.291
=	0.03

BioLight Life Sciences's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.258	-	0.823	-	0.137)	/	58.851
=	0.02

BioLight Life Sciences (NAS:BOLT) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

BioLight Life Sciences Net Cash per Share Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLight Life Sciences (BioLight Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

BOLT:Israel

Address

Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101

Website

http://www.bio-light.co.il

BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.